Advertisement

U.S. Markets closed

S&P Futures
5,888.25
-4.25(-0.07%)
Dow Futures
43,045.00
-124.00(-0.29%)
Nasdaq Futures
20,521.50
-20.50(-0.10%)
Russell 2000 Futures
2,244.80
-1.40(-0.06%)
Crude Oil
72.24
+0.15(+0.21%)
Gold
2,752.70
-7.10(-0.26%)

Immuneering Corporation (IMRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

2.2000

+0.0400

(+1.85%)

At close: 04:00PM EDT

2.0900

-0.11

(-5.00%)

After hours:

06:47PM EDT

Trade prices are not sourced from all markets

All

Zacks
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.
GlobeNewswire
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients - -Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year-end - CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universa